Skip to main content
letter
. 2024 Mar 14;109(7):2297–2302. doi: 10.3324/haematol.2023.284109

Figure 3.

Figure 3.

Landmark progression-free survival analysis stratified by minimal residual disease evaluated at different time points. (A) Overall minimal residual disease (MRD) at early restaging after 3 bendamustine rituximab courses (ER). (B) Overall MRD at end of treatment (EOT). (C) Overall MRD at 1-year follow-up (FU-1). (D) Peripheral blood MRD at ER. PFS: progression-free survival; overall MRD: at least 1 MRD-positive sample (either bone marrow or peripheral blood); MRD-: unmeasurable MRD.